284 related articles for article (PubMed ID: 25578962)
21. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
22. Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors.
Caswell JL; Camarda R; Zhou AY; Huntsman S; Hu D; Brenner SE; Zaitlen N; Goga A; Ziv E
Hum Mol Genet; 2015 Dec; 24(25):7421-31. PubMed ID: 26472073
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
24. RON alternative splicing regulation in primary ovarian cancer.
Mayer S; Hirschfeld M; Jaeger M; Pies S; Iborra S; Erbes T; Stickeler E
Oncol Rep; 2015 Jul; 34(1):423-30. PubMed ID: 25997828
[TBL] [Abstract][Full Text] [Related]
25. Alternative splicing: an emerging topic in molecular and clinical oncology.
Pajares MJ; Ezponda T; Catena R; Calvo A; Pio R; Montuenga LM
Lancet Oncol; 2007 Apr; 8(4):349-57. PubMed ID: 17395108
[TBL] [Abstract][Full Text] [Related]
26. RNA splicing, cell signaling, and response to therapies.
Abou Faycal C; Gazzeri S; Eymin B
Curr Opin Oncol; 2016 Jan; 28(1):58-64. PubMed ID: 26575690
[TBL] [Abstract][Full Text] [Related]
27. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
28. Identification of alternative splicing markers for breast cancer.
Venables JP; Klinck R; Bramard A; Inkel L; Dufresne-Martin G; Koh C; Gervais-Bird J; Lapointe E; Froehlich U; Durand M; Gendron D; Brosseau JP; Thibault P; Lucier JF; Tremblay K; Prinos P; Wellinger RJ; Chabot B; Rancourt C; Elela SA
Cancer Res; 2008 Nov; 68(22):9525-31. PubMed ID: 19010929
[TBL] [Abstract][Full Text] [Related]
29. Tissue stiffness regulates serine/arginine-rich protein-mediated splicing of the extra domain B-fibronectin isoform in tumors.
Bordeleau F; Califano JP; Negrón Abril YL; Mason BN; LaValley DJ; Shin SJ; Weiss RS; Reinhart-King CA
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8314-9. PubMed ID: 26106154
[TBL] [Abstract][Full Text] [Related]
30. Identification of constrained cancer driver genes based on mutation timing.
Sakoparnig T; Fried P; Beerenwinkel N
PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
[TBL] [Abstract][Full Text] [Related]
31. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
32. The gene encoding the splicing factor SF2/ASF is a proto-oncogene.
Karni R; de Stanchina E; Lowe SW; Sinha R; Mu D; Krainer AR
Nat Struct Mol Biol; 2007 Mar; 14(3):185-93. PubMed ID: 17310252
[TBL] [Abstract][Full Text] [Related]
33. A Simple Model-Based Approach to Inferring and Visualizing Cancer Mutation Signatures.
Shiraishi Y; Tremmel G; Miyano S; Stephens M
PLoS Genet; 2015 Dec; 11(12):e1005657. PubMed ID: 26630308
[TBL] [Abstract][Full Text] [Related]
34. Alternative splicing of synuclein gamma in endometrial cancer: identification of a novel isoform.
Schaal K; Hirschfeld M; Bronsert P; Füllgraf H; Jäger M; Herde B; Nöthling C; Mayer S; Erbes T; Stickeler E
Oncotarget; 2015 Sep; 6(26):22553-63. PubMed ID: 26265438
[TBL] [Abstract][Full Text] [Related]
35. The landscape and therapeutic relevance of cancer-associated transcript fusions.
Yoshihara K; Wang Q; Torres-Garcia W; Zheng S; Vegesna R; Kim H; Verhaak RG
Oncogene; 2015 Sep; 34(37):4845-54. PubMed ID: 25500544
[TBL] [Abstract][Full Text] [Related]
36. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
Chang MT; Asthana S; Gao SP; Lee BH; Chapman JS; Kandoth C; Gao J; Socci ND; Solit DB; Olshen AB; Schultz N; Taylor BS
Nat Biotechnol; 2016 Feb; 34(2):155-63. PubMed ID: 26619011
[TBL] [Abstract][Full Text] [Related]
37. Aberrant and alternative splicing in cancer.
Venables JP
Cancer Res; 2004 Nov; 64(21):7647-54. PubMed ID: 15520162
[TBL] [Abstract][Full Text] [Related]
38. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types.
Bianchi AB; Hara T; Ramesh V; Gao J; Klein-Szanto AJ; Morin F; Menon AG; Trofatter JA; Gusella JF; Seizinger BR
Nat Genet; 1994 Feb; 6(2):185-92. PubMed ID: 8162073
[TBL] [Abstract][Full Text] [Related]
39. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes.
Dowhan DH; Harrison MJ; Eriksson NA; Bailey P; Pearen MA; Fuller PJ; Funder JW; Simpson ER; Leedman PJ; Tilley WD; Brown MA; Clarke CL; Muscat GE
Endocr Relat Cancer; 2012 Aug; 19(4):509-26. PubMed ID: 22673335
[TBL] [Abstract][Full Text] [Related]
40. A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1.
Hollander D; Donyo M; Atias N; Mekahel K; Melamed Z; Yannai S; Lev-Maor G; Shilo A; Schwartz S; Barshack I; Sharan R; Ast G
Genome Res; 2016 Apr; 26(4):541-53. PubMed ID: 26860615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
